Total Payments
$371,500
2024 Payments
$13,043
Companies
28
Transactions
425
Medicare Patients
1,967
Medicare Billing
$399,702
Payment Breakdown by Category
Consulting$183,064 (49.3%)
Other$144,380 (38.9%)
Travel$26,348 (7.1%)
Food & Beverage$11,688 (3.1%)
Education$5,746 (1.5%)
Research$274.51 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $183,064 | 84 | 49.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $139,420 | 39 | 37.5% |
| Travel and Lodging | $26,348 | 79 | 7.1% |
| Food and Beverage | $11,688 | 208 | 3.1% |
| Education | $5,746 | 11 | 1.5% |
| Honoraria | $4,460 | 2 | 1.2% |
| Grant | $499.96 | 1 | 0.1% |
| Unspecified | $274.51 | 1 | 0.1% |
Payments by Type
General
$371,226
424 transactions
Research
$274.51
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $89,166 | 114 | $0 (2024) |
| TESARO, Inc. | $84,423 | 76 | $0 (2019) |
| Genentech USA, Inc. | $44,048 | 34 | $0 (2019) |
| Clovis Oncology, Inc. | $41,671 | 56 | $0 (2021) |
| Merck Sharp & Dohme LLC | $36,198 | 41 | $0 (2024) |
| Eisai Inc. | $29,133 | 24 | $0 (2024) |
| GlaxoSmithKline, LLC. | $25,502 | 28 | $0 (2024) |
| Aadi Bioscience, Inc. | $5,673 | 4 | $0 (2023) |
| Seagen Inc. | $3,830 | 4 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $2,571 | 5 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,043 | 29 | GlaxoSmithKline, LLC. ($8,093) |
| 2023 | $12,622 | 25 | GlaxoSmithKline, LLC. ($8,291) |
| 2022 | $12,049 | 20 | AstraZeneca Pharmaceuticals LP ($4,094) |
| 2021 | $27,646 | 17 | Eisai Inc. ($10,636) |
| 2020 | $24,626 | 19 | Eisai Inc. ($8,594) |
| 2019 | $62,544 | 89 | AstraZeneca Pharmaceuticals LP ($26,066) |
| 2018 | $111,061 | 125 | TESARO, Inc. ($31,892) |
| 2017 | $107,910 | 101 | TESARO, Inc. ($39,351) |
All Payment Transactions
425 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Arthrex, Inc. | Arthrex (Device) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Capital Consumables - Consumables - Legacy Synergy Resection System - Specialty | ||||||
| 12/05/2024 | Arthrex, Inc. | Arthrex (Device) | Food and Beverage | In-kind items and services | $103.33 | General |
| Category: Imaging & Resection - Equipment - Nano Systems - Nano Equipment | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $122.28 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Oncology | ||||||
| 11/05/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.28 | General |
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: Oncology | ||||||
| 07/31/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: Oncology | ||||||
| 07/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 04/24/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Oncology | ||||||
| 03/31/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $274.51 | Research |
| Study: Ph 1b study of cobimetinib and PARP inhibitor with or without atezolizumab in PSOC • Category: BioOncology | ||||||
| 03/17/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $42.66 | General |
| 03/15/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $71.66 | General |
| 03/15/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $20.73 | General |
| 03/12/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $31.14 | General |
| Category: Oncology | ||||||
| 03/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $26.19 | General |
| Category: ONCOLOGY | ||||||
| 03/03/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| Category: Oncology | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: Oncology | ||||||
| 02/13/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: ONCOLOGY | ||||||
| 01/26/2024 | ImmunoGen, Inc. | ELAHERE (Drug) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: ONCOLOGY | ||||||
| 01/26/2024 | ImmunoGen, Inc. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $79.00 | General |
| Category: ONCOLOGY | ||||||
| 01/24/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $123.60 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Ph 1b study of cobimetinib and PARP inhibitor with or without atezolizumab in PSOC | F. Hoffmann-La Roche AG | $274.51 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 486 | 1,276 | $598,736 | $95,731 |
| 2022 | 11 | 353 | 593 | $337,540 | $80,613 |
| 2021 | 17 | 541 | 1,266 | $564,347 | $104,877 |
| 2020 | 20 | 587 | 8,339 | $768,732 | $118,480 |
Total Patients
1,967
Total Services
11,474
Medicare Billing
$399,702
Procedure Codes
65
All Medicare Procedures & Services
65 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 156 | 336 | $95,760 | $30,657 | 32.0% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 30 | 30 | $121,591 | $21,406 | 17.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 68 | $25,280 | $9,168 | 36.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 56 | 56 | $23,420 | $6,746 | 28.8% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2023 | 25 | 25 | $79,250 | $6,546 | 8.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 16 | 53 | $33,490 | $5,163 | 15.4% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2023 | 28 | 28 | $31,950 | $4,446 | 13.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $8,540 | $2,556 | 29.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $8,160 | $2,065 | 25.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 32 | $6,240 | $1,714 | 27.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 25 | $7,500 | $1,536 | 20.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 15 | $4,950 | $1,417 | 28.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $3,575 | $975.59 | 27.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 12 | 32 | $7,040 | $704.32 | 10.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 13 | $2,730 | $512.59 | 18.8% |
| J3490 | Unclassified drugs | Office | 2023 | 11 | 21 | $1,760 | $70.27 | 4.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 11 | 500 | $137,500 | $48.99 | 0.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 125 | 223 | $63,555 | $20,263 | 31.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 55 | 143 | $51,480 | $19,833 | 38.5% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2022 | 22 | 22 | $86,320 | $16,233 | 18.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 13 | 48 | $29,760 | $5,050 | 17.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 35 | 35 | $14,350 | $4,323 | 30.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $12,360 | $4,088 | 33.1% |
| 38571 | Removal of lymph nodes of both sides of pelvis using an endoscope | Facility | 2022 | 14 | 14 | $44,380 | $3,727 | 8.4% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2022 | 18 | 18 | $17,050 | $2,724 | 16.0% |
About Dr. Matthew Powell, MD
Dr. Matthew Powell, MD is a Gynecologic Oncology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609894187.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Powell, MD has received a total of $371,500 in payments from pharmaceutical and medical device companies, with $13,043 received in 2024. These payments were reported across 425 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($183,064).
As a Medicare-enrolled provider, Powell has provided services to 1,967 Medicare beneficiaries, totaling 11,474 services with total Medicare billing of $399,702. Data is available for 4 years (2020–2023), covering 65 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Location Saint Louis, MO
- Active Since 07/17/2006
- Last Updated 04/17/2025
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1609894187
Products in Payments
- LYNPARZA (Drug) $88,203
- ZEJULA (Drug) $72,273
- Avastin (Biological) $44,048
- Rubraca (Drug) $41,576
- Lenvima (Drug) $29,037
- KEYTRUDA (Biological) $11,485
- Fyarro (Drug) $3,106
- FYARRO (Drug) $2,567
- ZEPZELCA (Drug) $1,800
- ELAHERE (Drug) $1,517
- Tecentriq (Biological) $274.51
- Tivdak (Drug) $272.48
- Da Vinci Surgical System (Device) $200.27
- Arthrex (Device) $143.33
- PRECISETUMOR (Device) $141.51
- YONDELIS (Drug) $138.58
- JEMPERLI (Biological) $137.66
- FLOSEAL (Biological) $124.73
- n.a. (Device) $117.50
- Wegovy (Drug) $100.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Saint Louis
Dr. Premal Thaker, Md, MD
Gynecologic Oncology — Payments: $343,223
Gynecologic Oncology $343,223
Dr. David Mutch, Md, MD
Gynecologic Oncology — Payments: $89,524
Gynecologic Oncology $89,524
Dr. Carolyn Mccourt, Md, MD
Gynecologic Oncology — Payments: $34,327
Gynecologic Oncology $34,327
Dan-Arin Silasi, Md, MD
Gynecologic Oncology — Payments: $27,564
Gynecologic Oncology $27,564
Dr. Dineo Khabele, Md, MD
Gynecologic Oncology — Payments: $21,978
Gynecologic Oncology $21,978
Shannon Grabosch, M.d, M.D
Gynecologic Oncology — Payments: $10,087
Gynecologic Oncology $10,087